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Background: Plasmodium vivax is one of the five species causing malaria in human beings, affecting around 391
million people annually. The development of an anti-malarial vaccine has been proposed as an alternative for
controlling this disease. However, its development has been hampered by allele-specific responses produced by the
high genetic diversity shown by some parasite antigens. Evaluating these antigens’ genetic diversity is thus essential
when designing a completely effective vaccine.
Methods: The gene sequences of Plasmodium vivax p12 (pv12) and p38 (pv38), obtained from field isolates in
Colombia, were used for evaluating haplotype polymorphism and distribution by population genetics analysis. The
evolutionary forces generating the variation pattern so observed were also determined.
Results: Both pv12 and pv38 were shown to have low genetic diversity. The neutral model for pv12 could not be
discarded, whilst polymorphism in pv38 was maintained by balanced selection restricted to the gene’s 5′ region.
Both encoded proteins seemed to have functional/structural constraints due to the presence of s48/45 domains,
which were seen to be highly conserved.
Conclusions: Due to the role that malaria parasite P12 and P38 proteins seem to play during invasion in
Plasmodium species, added to the Pv12 and Pv38 antigenic characteristics and the low genetic diversity observed,
these proteins might be good candidates to be evaluated in the design of a multistage/multi-antigen vaccine.
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Anti-malarial vaccineBackground
Malaria is a disease caused by protozoan parasites from
the Plasmodium genus, five of which cause the disease
in human beings (Plasmodium falciparum, Plasmodium
vivax, Plasmodium ovale, Plasmodium malariae and
Plasmodium knowlesi) [1,2]. This parasite is transmitted
by the bite of an infected Anopheles female mosquito.
Around 3.3 billon people are at risk of malaria annually,
mainly in tropical and subtropical areas of the world,* Correspondence: mapatarr.fidic@gmail.com
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article, unless otherwise stated.children aged less than five years and pregnant women
being the most vulnerable [3]. Plasmodium falciparum is
responsible for the disease’s most lethal form, being pre-
dominantly found on the African continent whilst P. vivax
is widely distributed around the world. Even though it has
been thought that infection caused by the latter species
was benign, recent studies have shown that P. vivax can
cause clinical complications [4]. It has been found that
2,488 million people are at risk of becoming infected by P.
vivax on the continents of Asia and America, 132 to 391
million cases occurring annually [5].
In spite of control strategies having been introduced in
different countries, malaria continues to be a public health
problem due to the parasite’s resistance to anti-malarial
treatments [6] and the vector’s resistance to insecticides
[7], among other causes. More effective measures haved Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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cluding the development of an anti-malarial vaccine.
Several antigens have been characterized as promising
candidates for inclusion in a vaccine [8,9], however, the
genetic diversity of some of them [10-18] has hampered
the development of such vaccine [19,20] as these genetic
variations provoke allele-specific responses [21,22] mak-
ing them become a mechanism for evading the immune
system [23]. It has been necessary to focus vaccine de-
velopment on conserved domains or antigens to avoid
such responses [24], since these regions could have func-
tional constraint and have had slower evolution [25].
Developing a multi-antigen vaccine against the para-
site’s blood stage has been focused on blocking all host-
pathogen interactions to stop merozoite entry to red
blood cells (RBC) [26]. A group of proteins anchored to
the membrane via glycosylphosphatidylinositol (GPI)
has been identified in P. falciparum, predominantly lo-
cated in detergent-resistant membrane (DRM) domains
[27,28]; they have been implicated in the parasite’s ini-
tial interaction with RBC [29-33] and some have been
considered as being candidates for being included in a
vaccine [34,35]. One group of proteins belonging to the
6-cystein (6-Cys) family is particularly noteworthy among
these DRMs (i.e., Pf12, Pf38, Pf41 and Pf92) as they have
been characterized by having s48/45 domains (ID in
PFAM: PF07422). Members of this family are expressed
during different parasite stages [28,36] and some of
them (e.g., Pf48/45, Pf230) have been considered as vac-
cine candidates for the sexual stage [36,37].
Pf12 and Pf38 are expressed during late stages of the
intra-erythrocyte cycle, each having two high binding pep-
tides, suggesting an active role during invasion of RBC
[30]. Orthologous genes encoding these proteins have
been characterized recently in P. vivax [38,39]. Both pro-
teins have a signal peptide, a GPI anchor sequence and
have been associated with DRMs [38,39]. Pv12 has two
s48/45 domains [39] whilst Pv38 has a single domain lo-
cated towards the C-terminal end [38]. These proteins
have been shown to be antigenic [38-40], suggesting that
they are exposed to the immune system, probably during
P. vivax invasion of RBC.
The present study involved a population genetics ana-
lysis for evaluating the genetic diversity of pv12 and
pv38 loci and the evolutionary processes generating this
variation pattern; the results revealed these antigens’ low
genetic diversity in the Colombian population, possibly
due to functional/structural constraints in s48/45 do-
mains. Since the proteins encoded by these genes share
structural characteristics with other vaccine candidates,
added to the fact that Pv12 and Pv38 are targets for the
immune response [38-40] and have conserved domains,
they should be considered when designing a multistage/
multi-antigen anti-malarial vaccine.Methods
Ethics statement
The parasitized DNA used in this study was extracted
from total blood collected from different Colombian areas
(Antioquia, Atlántico, Bogotá, Caquetá, Cordoba, Chocó,
Guainía, Guaviare, Magdalena, Meta, Nariño, and Tolima)
from 2007 to 2010. All P. vivax-infected patients who pro-
vided blood samples were notified about the object of the
study and signed an informed consent form if they agreed
to participate. All procedures involved in taking blood
samples were approved by Fundación Instituto de Inmu-
nología de Colombia (FIDIC) ethics committee.
Parasitized DNA presence and integrity
Parasitized DNA presence and integrity in 100 samples
stored at -20°C (2007-2010) at FIDIC (from different
areas of Colombia) were evaluated by 18S ribosomal
RNA gene amplification using specific primers for P.
vivax (SSU-F 5′-ATGAACGAGATCTTAACCTGC-3′
and SSU-R 5′-CATCACGATATGTA5TGATAAAGAT-
TACC-3′) in a touchdown PCR [41]. The reaction con-
tained: 1x Mango Taq reaction buffer (Bioline), 2.5 mM
MgCl2, 0.25 mM dNTPs, 0.5 mM of each primer, 0.1 U
Mango Taq DNA polymerase (Bioline) and 10-40 ng gDNA
in 10 mL final volume. The PCR thermal profile was: one
initial denaturing cycle at 95°C (5 min), followed by ten
cycles at 95°C (20 sec), annealing at 65°C (30 sec) and an
extension step at 72°C (45 sec). Annealing temperature was
reduced by 1°C in each cycle until reaching 55°C; 35 add-
itional cycles were run at this temperature followed by a
final extension cycle at 72°C (10 min). PCR products were
visualized by electrophoresis on 1.5% agarose gel in 1×
TAE, using 1 μL SYBR-Safe (Invitrogen).
Identifying infection caused by single Plasmodium vivax
strain
Infection by the single P. vivax strain was identified by
PCR-RFLP of the pvmsp-1 polymorphic marker. The
pvmsp-1 gene fragment 2 (blocks 6, 7 and 8) was ampli-
fied using direct 5′-AAAATCGAGAGCATGATCGCC
ACTGAGAAG-3′ and reverse 5′-AGCTTGTACTTTC
CATAGTGGTCCAG-3′ primers [42]. The amplified
fragments were digested with Alu I and Mnl I restric-
tion enzymes, as described elsewhere [42]. The products
were visualized by electrophoresis on 3% agarose gel in
1× TAE, using 1 μL SYBR-Safe (Invitrogen).
PCR amplification of pv12 and pv38 genes
A set of primers was designed for amplifying each of the
genes based on Sal-I reference strain sequences (acces-
sion numbers in PlasmoDB: PVX_113775 for pv12 and
PVX_097960 for pv38). The following primers were
used: for pv12, pv12-direct 5′-GTACCGCTTAACAC
CGC-3′ and pv12-reverse 5′-GCACTACATTATAAAG
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TCTTTCACCGCTTC-3′ and pv38-reverse 5′-CACAC
ATTAACGCTGCTTCG-3′. The PCR reaction mixture
contained 10 mM Tris HCL, 50 mM KCl (GeneAmp
10× PCR Buffer II [Applied Biosystems]), 1.5 mM MgCl2,
0.2 mM of each dNTP, 0.5 μM of each primer, 0.76 U
Amplitaq Gold DNA polymerase (Applied Biosystems)
and 10-40 ng gDNA in a 50 μL final volume. The PCR
thermal profile was as follows: one cycle at 95°C (7 min),
40 cycles at 95°C (20 sec), 56°C (30 sec), 72°C (1 min) and
a final extension cycle at 72°C (10 min). PCR products
were purified using a commercial UltraClean PCR Clean-
up kit (MO BIO). The purified PCR products were se-
quenced in both directions with the amplification primers
using the BigDye method with capillary electrophoresis,
using ABI-3730 XL (MACROGEN, Seoul, South Korea).
Two independent PCR products were sequenced to en-
sure that errors were ruled out.
Analysing genetic diversity
The electropherograms obtained by sequencing were
analysed and forward and reverse sequences were as-
sembled using CLC Main workbench software v.5 (CLC
bio, Cambridge, MA, USA). The pv12 and pv38 genes
were analysed and compared to reference sequences
obtained from several sequencing projects [43,44] (acces-
sion numbers, pv12: XM_001616094.1, AFBK01001496.1,
AFNI01000939.1, AFMK01001167.1 and AFNJ01001458.1;
pv38: XM_001613202.1, AFNI01000834.1, AFNJ010000
90.1, AFMK01001057.1 and AFBK01001340.1) or those
reported in the GenBank database (accession numbers
for pv12: GU476521.1; and for pv38: JF427569.1 and
JF427570.1). Gene Runner software was used for trans-
lating the sequences for deducing the amino acid se-
quences. These sequences were then aligned using the
MUSCLE algorithm [45], and manually edited. Amino
acid alignment was then used for inferring DNA using
PAL2NAL software [46].
DnaSP software (v.5) [47] was used for evaluating intra-
population genetic polymorphism by calculating: the num-
ber of polymorphic segregating sites (Ss), the number of
singleton sites (s), the number of parsimony-informative
sites (Ps), the number of haplotypes (H), haplotype diver-
sity (Hd, which was multiplied by (n-1)/n according to
Depaulis and Veuille [47,48]), the Watterson estimator
(θw) and nucleotide diversity per site (π). DNA sequence
variation was calculated using the sequences obtained
from the aforementioned databases, plus the Colombian
ones (worldwide isolates, global diversity) and just those
obtained for the Colombian population (local diversity).
The frequency for each Colombian haplotype was also es-
timated by count and year.
Two test families were used for evaluating the neutral
molecular evolution model for the Colombian population:(1) frequency spectrum test, and (2) haplotype test. The
former involved calculating Tajima’s D statistics [49], Fu
and Li’s D* and F* [50] and Fay and Wu’s H statistic [51].
Tajima’s D statistic compares the difference between seg-
regating sites and the average of nucleotide differences
between two randomly taken sequences. Fu and Li’s D*
statistic takes the difference between the number of
singleton sites and the total of mutations, whilst F* takes
the difference between the number of singleton sites and
the average of nucleotide differences between two ran-
domly taken sequences. Fay and Wu’s H statistic is based
on the difference of the average number of nucleotide dif-
ferences between pairs of sequences and the frequency of
the derived variants. Fu’s Fs statistic [52], K-test and H-
test [48] are tests for calculating haplotype distribution.
The Fs statistic compares the number of haplotypes ob-
served to the expected number of haplotypes in a random
sample. K-test and H-test [48] are based on haplotype
number and haplotype diversity, respectively; these statis-
tics are conditioned by sample size (n) and the number of
segregating sites (Ss). Test significance was determined by
coalescence simulations using DnaSP (v.5) [47] and ALLE-
LIX software (kindly supplied by Dr Sylvain Mousset).
Sites having gaps were not taken into account in any of
the tests performed.
The effect of natural selection was evaluated regarding
intra and interspecies; the average number of non-
synonymous substitutions per non-synonymous site (dN)
and the average number of synonymous substitutions per
synonymous site (dS) were calculated for the former by
using the modified Nei-Gojobori method [53]. The signifi-
cant differences between the above were determined by
using Fisher’s exact test (suitable for dN and dS < 10) and
codon-based Z-test incorporated in MEGA software (v.5)
[54]. Differences between dN and dS per site were calcu-
lated by using SLAC, FEL, REL [55], IFEL [56], MEME
[57], and FUBAR [58] methods. The average number of
non-synonymous divergence substitutions per non-
synonymous site (KN) and the average number of syn-
onymous divergence substitutions per synonymous site
(KS) were calculated using the modified Nei-Gojobori
method [53], with Jukes-Cantor correction [59], to infer
natural selection signals which may have prevailed dur-
ing malarial parasite evolutionary history (interspecies;
using Plasmodium cynomolgi (accession number BAEJ
01001076.1) and P. knowlesi (accession number NC_011
912.1) orthologous sequences). The significant differ-
ences between KN and KS were determined by using a
codon-based Z-test incorporated in MEGA software
(v.5) [54]. The McDonald-Kreitman test [60] was also
calculated; this is based on a comparison of intraspecific
polymorphism to interspecific divergence (using Plasmo-
dium cynomolgi (accession number BAEJ01001076.1) and
P. knowlesi (accession number NC_011912.1) orthologous
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[61], which takes Jukes-Cantor divergence correction
into account [59]. All the above tests were calculated
using the sequences obtained from the databases plus
the Colombian ones and just those obtained for the
Colombian population.
ZnS [62] and ZZ [63] statistics were calculated for
evaluating the influence of linkage disequilibrium (LD)
and intragenic recombination, respectively. The minimum
number of recombination (Rm) events was also calculated;
this included calculating effective population size and the
probability of recombination between adjacent nucleotides
per generation [64]. Additionally, the GARD method [65]
available at the Datamonkey web server [66] was per-
formed. These tests were performed using the sequences
obtained from the Colombian population.
Results and discussion
The presence of genomic DNA (gDNA) and identification
of single Plasmodium vivax strain infection
An 18S subunit rRNA gene fragment was amplified from
100 samples of P. vivax collected from different areas of
Colombia and stored from 2007 to 2010. Seventy-seven
samples revealed an amplicon at the expected size, indi-
cating the presence of P. vivax gDNA. A region of the
pvmsp-1 gene was then amplified and digested with re-
striction enzymes, showing that seven of the 77 samples
proving positive for P. vivax had multiple infections. Only
70 samples were thus considered for later analysis. Due to
the low number of samples collected from some areas, they
were grouped according to geographical localisation and
epidemiological conditions (South-west: Chocó, Nariño;
South-east: Caquetá, Guainía, Guaviare, Meta; Midwest:
Bogota, Tolima; North-west: Atlántico, Antioquia Cordoba,
Magdalena).
Genetic diversity in pv12
Seventy samples amplified a 1,200 base pair (bp) frag-
ment corresponding to the pv12 gene (South-west n = 6;
South-east: n = 20; Midwest: n = 8; North-west: n =36).
These amplicons were purified and sequenced; the se-
quences were then analysed, compared to different refer-
ence sequences obtained from various sequencing projects
[43,44] and those having a different haplotype were de-
posited in the GenBank database (accession numbers
KF667328 and KF667329).
Four single nucleotide polymorphisms (SNP) were ob-
served throughout the pv12 gene sequence (Figure 1A)
located in positions 375 (N125K), 379 (T127A), 539
(L180W) and 662 (N221S). Only one SNP (nucleotide
375) was found in the Colombian population. A repeat
region was observed; it was formed by previously re-
ported amino acids N[A/V][H/Q] [39], in which an in-
sertion was observed in the North Korean sequence(Figure 1A, haplotype 1) and deletions in the Colombian
sequences (Figure 1A, haplotypes 2 and 3).
Six haplotypes were found in pv12 (Figure 1A and
Table 1) around the world, four of which are present in
Colombia at 8.7, 5.8, 10.1, and 75.4% frequency for
haplotypes 2, 3, 5 and 6, respectively. Haplotypes 2, 5
and 6 were present in the different Colombian locations
(Additional file 1), haplotype 6 being the most predomin-
ant per year (2007 n = 9; 2008 n = 17; 2009 n = 15; 2010
n = 29) and per location, having higher than 70% fre-
quency (Figure 2A and Additional file 1). The remaining
haplotypes were absent or had low frequency (Figure 2A
and Additional file 1). Interestingly, haplotype 3 was
present in Colombia during 2009 but absent in the other
years studied (Figure 2A). The percentage of samples
from the South-east area (some of them presenting
haplotype 3) was greater than for other years, suggesting
that haplotype 3 was restricted to a particular geograph-
ical area (Additional file 1) and/or that this had very low
frequency in different Colombian subpopulations. Haplo-
type 2 was absent from 2007 to 2008 but present between
2009 and 2010 (Figure 2A); differently to haplotype 3, this
haplotype was present everywhere, except in the South-
west location (Additional file 1). This appeared to be
consistent with previous studies which have reported
numerous private haplotypes in American Plasmodium
vivax populations [67]. These results suggested that the
Colombian population had one predominant pv12 haplo-
type and several low frequency alleles, which are geo-
graphically isolated or were not detected during some
periods of time. Since P. vivax populations within coun-
tries seem to be strongly structured [67], new pv12 haplo-
types could appear in other parasite populations.
This gene had 0.0004 ± 0.0001 global nucleotide diver-
sity (π) and 0.0003 ± 0.0001 for the Colombian popula-
tion (Table 1). This value was about 2.5 times less than
that reported for its orthologue in P. falciparum (π =
0.001) [68]; however, both values were low when com-
pared to other membrane proteins [10-14,17], suggesting
that this gene is highly conserved in different Plasmo-
dium species. This value places pv12 among the most
conserved antigen-encoding genes characterized to date
in P. vivax.
Mutations in pv12 appear to be selectively neutral
Several tests for evaluating the hypothesis that mutations
in pv12 are neutral were performed. No significant values
were found for the Tajima, Fu and Li, Fay and Wu or Fu
tests (Table 2); likewise, the Colombian population’s num-
ber of haplotypes (4) and haplotype diversity (0.406 ±
0.07) (Table 2) were as expected under neutrality accord-
ing to the K-test and H-test. Since neutrality could not be
ruled out, the mutations or haplotypes found in pv12
could have been randomly fixed; this might explain the
Figure 1 pv12 and pv38 haplotype alignment. A. Alignment of the six haplotypes found in the pv12 gene. Haplotypes 2, 3, 5 and 6 were
found in the Colombian population. B. Alignment of the 17 haplotypes found in pv38, 14 of them found in the Colombian population
(haplotypes 1, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, and 17). The dots indicate nucleotide identity and dashes indicate nucleotide absence.
Numbering is based on the Sal-I reference sequence.
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ent alleles could have become fixed in different popula-
tions according to the neutral hypothesis. Alternatively,
the geographical isolation of haplotype 3 could have re-
sulted from the structured P. vivax population in America,
where haplotypes may have diversified in situ.
Natural selection in pv12
The gene was split into two regions: region A, nucleotides
1-546 (amino acids 1-182 including one s48/45 domain)
and region B, nucleotides 547-1,095 (amino acids 183-365
including the other s48/45 domain). Synonymous substi-
tution per synonymous site (dS) and non-synonymous
substitution per non-synonymous site rates (dN) were cal-
culated using the gene’s total length to evaluate whether
natural selection had any effect on pv12 evolution. Full
length gene and split regions had non-significant values
(Table 3); likewise, when dN and dS were estimated for
s48/45 domains, no significant values were observedTable 1 Estimators for pv12 and pv38 global and local
genetic diversity
n Gene Sites Ss S Ps H θw (sd) π (sd)
Worldwide isolates
76 pv12 927 4 3 1 6 0.0009 (0.0005) 0.0004 (0.0001)
53 pv38 1,035 9 1 8 17 0.0019 (0.0006) 0.0026 (0.0002)
Colombian population
70 pv12 1,047 1 0 1 4 0.0002 (0.0002) 0.0003 (0.0001)
46 pv38 1,062 8 0 8 14 0.0017 (0.0006) 0.0024 (0.0002)
Estimators of genetic diversity were calculated using the sequences obtained
from databases plus the Colombian ones (worldwide isolates, global diversity)
and just those obtained for the Colombian population (Colombian population,
local diversity). n: number of isolates, sites: total of sites analysed excluding
gaps, Ss: number of segregating sites, S: number of singleton sites, Ps: number
of informative-parsimonious sites, H: number of haplotypes, θw: Watterson
estimator, π: nucleotide diversity per site. sd: standard deviation.(Additional file 2), contrary to that suggested for pf12,
where purifying selection action has been reported [69].
The Datamonkey server was used for calculating dN and
dS rates for each codon; no selected sites were found, indi-
cating (once more) that the gene did not appear to deviate
from neutrality.
However, assessing how natural selection acts on low
genetic diversity antigens is not easy [70]; the fact that
Plasmodium vivax shares its most recent common ances-
tor with parasites infecting primates (e.g. P. cynomolgi and
P. knowlesi) led to inferring patterns which may have
prevailed during their evolutionary history [70,71]. When
synonymous divergence substitution per synonymous site
(KS) and non-synonymous divergence substitution per
non-synonymous site (KN) rates were calculated, a signifi-
cantly higher KS than KN was found (Table 4). Moreover, a
sliding window for ω (dN/dS and/or KN/KS) revealed < 1
values throughout the gene (Figure 3), which could have
been a consequence of negative selection. Moreover,
significant values were observed when the McDonald-
Kreitman (MK) test was used for comparing intraspe-
cific polymorphism and interspecific divergence (using
all the haplotypes found for this gene): PN/PS > DN/DS
(Table 5), revealing (similar to KS rates) a large accumula-
tion of synonymous substitutions between species, which
could be interpreted as negative selection. Such accumula-
tion of interspecies synonymous substitutions suggested
that evolution tried to maintain protein structure by elim-
inating all deleterious mutations. However, when the MK
test was done with haplotypes found in Colombia (and in
spite of the accumulation of synonymous substitutions be-
tween species), no significant values were observed in this
population (Table 5). Although Pv12 is exposed to the im-
mune system [39,40], it had a high level of conservation.
This pattern could have been because pv12 had diverged
Figure 2 Frequency of the pv12 and pv38 haplotypes present in the Colombian population. A. Frequency per year for the four pv12
haplotypes found in the Colombian population: n = 9 in 2007, n = 17 in 2008, n = 15 in 2009 and n = 29 in 2010. B. Frequency per year for the 14
pv38 haplotypes found in the Colombian population. n = 6 in 2007, n = 6 in 2008, n = 8 in 2009 and n = 26 in 2010.
Forero-Rodríguez et al. Malaria Journal 2014, 13:58 Page 6 of 12
http://www.malariajournal.com/content/13/1/58by negative selection, due to a possible functional/struc-
tural constraint imposed by the presence of s48/45 do-
mains [72] which seem to play an important role during
host cell recognition [30,69,72].
Genetic diversity in pv38
Only 46 out of 70 samples could be amplified for the
pv38 gene, giving a 1,121 bp fragment (South-west n = 6;
South-east: n = 13; Midwest: n = 4; North-west: n = 23).
The 46 sequences obtained from Colombian isolates were
compared to and analysed regarding reference sequences
obtained from different regions of the world [43,44].
Colombian sequences that have a different haplotype to
that of previously reported ones can be found in GenBank
(accession numbers KF667330-KF667340).
Nine SNPs were observed in the pv38 gene (Figure 1B),
most of which were no-synonymous (nucleotides: 88
(R30S), 206/207 (A69V), 209 (R70L), 524/525 (T175N),
880 (M294L), and 998 (S333N)), similar to that found in
Pf38 [73]. Positions 525 and 969 produced synonymous
substitutions (a change in protein sequence was generated
when the substitution in position 525 was accompanied
with another one in position 524). The parasite population
in Colombia has eight of these nine SNPs, all being
informative-parsimonious sites. Similar to that reportedTable 2 pv12 and pv38 neutrality, linkage disequilibrium and
N Gene Tajima Fu and Li Fay and
Wu’s HD D* F*
70 pv12 0.365 0.516 0.548 0.000
46 pv38 1.147 1.304 1.473 −1.275 −
n: number of isolates.
*: p < 0.05.
ND: not determined.
sd: standard deviation.for its orthologue in P. falciparum [73], most substitutions
were found in the gene’s 5′ region.
Seventeen haplotypes were identified from alignment
(including sequences from different regions of the world)
(Figure 1B), 14 of which were found in Colombia’s para-
site population at different frequencies: 11% haplotype 1,
4% haplotype 5, 2% haplotype 6, 20% haplotype 7, 15%
haplotype 8, 7% haplotype 9, 2% haplotype 10, 4% haplo-
type 11, 13% haplotype 12, 4% haplotype 13, 2% haplotype
14, 4% haplotype 15, 7% haplotype 16, and 4% haplotype
17. Most haplotypes were found in intermediate frequen-
cies per year (2007 n = 6; 2008 n = 6; 2009 n = 8; 2010 n =
26) and none exceeded 50% (Figure 2B). The absence of
some haplotypes in determined years, or in some loca-
tions, could not just have been due to the low frequency
which they might have had but also to the difference in
the number of samples for each year (n = 6 in 2007, n =
6 in 2008, n = 8 in 2009 and n = 26 in 2010) or because
American P. vivax populations appear to be structured
and therefore several privative haplotypes might be
found [67].
π in this gene was 0.0026 ± 0.0002 worldwide and
0.0024 ± 0.0002 in the Colombian population (Table 1),
this being 1.3 times lower than that for its orthologue in
P. falciparum (π = 0.0034) [68,73] showing that the pv38recombination tests for the Colombian population
Fu’s
Fs
K-test H-test (sd) Zns ZZ RM
0.902 4 0.406 (0.07) ND ND 0
4.451 14* 0.890 (0.02)* 0.107 0.125 2
Table 3 Synonymous substitution per synonymous site rate (dS) and non-synonymous substitution per
non-synonymous site rate (dN) for pv12 and pv38 genes
n Gene Region A Region B Full length gene
dS (se) dN (se) dS (se) dN (se) dS (se) dN (se)
Worldwide isolates
76 pv12 0.000 (0.000) 0.001 (0.001) 0.000 (0.000) 0.000 (0.000) 0.000 (0.000) 0.001 (0.000)
53 pv38 0.001 (0.001) 0.003 (0.002) 0.006 (0.004) 0.001 (0.001) 0.004 (0.002) 0.002 (0.001)
Colombian population
70 pv12 0.000 (0.000) 0.001 (0.001) 0.000 (0.000) 0.000 (0.000) 0.000 (0.000) 0.000 (0.000)
46 pv38 0.001 (0.001) 0.003 (0.002) 0.005 (0.004) 0.001 (0.001) 0.004 (0.002) 0.002 (0.001)
dN and dS rates were estimated by using sequences obtained from databases together with Colombian ones (worldwide isolates) and just with those obtained in
the Colombian population. n: number of isolates. pv12: region A, nucleotides 1-546 and region B, nucleotides 547-1,095. pv38: region A, nucleotides 1-459 and
region B, nucleotides 460-1,065. se: standard error. No statistically significant differences were found.
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http://www.malariajournal.com/content/13/1/58gene had low diversity, at least in the two main species
affecting human beings.
Deviation from the neutral model of molecular evolution
in pv38
Tajima’s D, Fu and Li’s D* and F*, Fay and Wu’s H and
Fu’s Fs neutrality tests did not reveal statistically signifi-
cant values (Table 2), suggesting that the gene might
follow the neutral evolution model. However, the pres-
ence of 14 haplotypes and 0.890 ± 0.02 haplotype diver-
sity in the Colombian population was greater than that
expected under neutrality according to K-test and H-Table 4 Synonymous divergence substitution per synonymou
substitution per non-synonymous site (KN) rate
P. vivax/P. C
n Gene s48/45 domain in region A
KS (se) KN (se)
Worldwide isolates
78 pv12 0.016 (0.003)† 0.005 (0.002) 0
54 pv38 - 0
Colombian isolates
71 pv12 0.018 (0.003)† 0.005 (0.001) 0
47 pv38 - 0
P. vivax/P. k
n Gene s48/45 domain in region A
KS (se) KN (se)
Worldwide isolates
78 pv12 0.025 (0.005)† 0.006 (0.002) 0
54 pv38 - 0
Colombian isolates
71 pv12 0.027 (0.006)† 0.006 (0.001) 0
47 pv38 - 0
KN and KS rates were estimated by using sequences obtained from databases (worl
the Colombian population. n: number of isolates. pv12 s48/45 domain in region A: n
s48/45 domain in region B: nucleotides 481-852; -: There are no s48/45 domains in
*: p < 0.000, †: p < 0.002.test results (Table 2). This suggested balanced ancestral
polymorphism [48], being similar to that reported for
the P. falciparum p38 gene which showed evidence of
balanced selection in 5’ region [73].
Natural selection in pv38
A modified Nei Gojobori method was used for calculat-
ing dN and dS rates for showing some type of selection
in the pv38 gene. Similar to that used regarding pv12,
the pv38 gene was divided into two regions: region A,
covering position 1-459 (amino acids 1-153) and region
B, nucleotides 460-1,065 (amino acids 154-355 includings site (KS) rate and non-synonymous divergence
ynomolgi
s48/45 domain in region B Full-length gene
KS (se) KN (se) KS (se) KN (se)
.019 (0.004)† 0.003 (0.001) 0.016 (0.002)* 0.004 (0.001)
.030 (0.007)† 0.005 (0.001) 0.031 (0.004)* 0.007 (0.001)
.021 (0.004)† 0.003 (0.001) 0.016 (0.002)* 0.005 (0.001)
.033 (0.007)† 0.006 (0.001) 0.033 (0.004)* 0.008 (0.001)
nowlesi
s48/45 domain in region B Full-length gene
KS (se) KN (se) KS (se) KN (se)
.020 (0.004)† 0.003 (0.001) 0.022 (0.003)* 0.005 (0.001)
.028 (0.006)† 0.005 (0.001) 0.034 (0.004)* 0.007 (0.001)
.022 (0.005)† 0.003 (0.001) 0.023 (0.002)* 0.005 (0.001)
.031 (0.007)† 0.005 (0.001) 0.038 (0.005)* 0.008 (0.001)
dwide isolates) together with Colombian ones, and just with those obtained in
ucleotides 82-471; pv12 s48/45 domain in region B: nucleotides 589-906; pv38
pv38 region A. Numbering is based on the Sal-I reference sequence.
Figure 3 Sliding window analysis for ω rates. The ω (dN/dS) values for Plasmodium vivax p12 and p38 are shown in blue, whereas the
divergence (ω: KN/KS) between Plasmodium vivax and Plasmodium cynomolgi (Pcyn) and Plasmodium vivax and Plasmodium knowlesi (Pkno) is
displayed in magenta and purple, respectively. A gene diagram is shown below the sliding window. Regions encoding signal peptides (brown),
GPI anchors (green), s48/45 domains (dark cyan) as well as the N[A/V][H/Q] repeat (black) are indicated. Non-synonymous (red) and synonymous
(orange) substitutions are shown with vertical lines above each gene.
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http://www.malariajournal.com/content/13/1/58the s48/45 domain). There were more dN substitutions in
region A than dS substitutions, whilst there were more dS
substitutions in region B than dN ones, even though no
significant values were observed (Table 4 and Additional
file 2). Selection tests by codon revealed positive selection
in codon 70 and negative selection in codons 175 and 323,
suggesting that the gene was influenced by selection.
When the long-term effect of natural selection was ex-
plored by comparing divergence rates (KS and KN), pv38
had a higher statistically significant KS rate than KNTable 5 McDonald-Kreitman test for evaluating the action of
P. vivax/P. cynom
Worldwide
Fixed Polymorphic PN/PS
pv12 Non-synonymous substitutions 78.66 4
Synonymous substitutions 190.23 0
pv38 Non-synonymous substitutions 85.90 6
Synonymous substitutions 257.31 3
Colombian p
pv12 Non-synonymous substitutions 93.05 1
Synonymous substitutions 197.20 0
pv38 Non-synonymous substitutions 89.22 5
Synonymous substitutions 248.66 3
The McDonald-Kreitman test was done using sequences obtained from databases (
obtained in the Colombian population. The interspecies divergence data were obta
Plasmodium cynomolgi and Plasmodium knowlesi. Significant values are shown in ita(Table 4), revealing ω values below 1 throughout the gene
(Figure 3), suggesting divergence by negative selection.
The McDonald-Kreitman test revealed statistically sig-
nificant values (Table 4), when intraspecific polymorphism
and interspecific divergence was compared, showing PN/
PS > DN/DS (p < 0.02). This result could have been the re-
sult of either a negative selection or a balanced selection
[61,74]. K-test and H-test results (Table 2) and the pres-
ence of different haplotypes at intermediate frequencies
(Figure 2B) suggested that it is most probable that pv38natural selection
olgi P. vivax/P. knowlesi
isolates
> DN/DS p-values Fixed Polymorphic PN/PS > DN/DS p-values
0.002 93.86 4 0.000
340.47 0
0.004 85.14 6 0.003
265.94 3
opulation
0.146 115.54 1 0.083
347.80 0
0.023 88.50 5 0.016
264.90 3
worldwide isolates) together with Colombian ones, and just with those
ined from comparing Plasmodium vivax sequences with two related species:
lics.
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http://www.malariajournal.com/content/13/1/58was influenced by balanced selection, similar to that re-
ported for P. falciparum [73]. Such selection seemed to be
domain specific. Significant values were observed for
region A (p = 0.014) when intraspecific polymorphism
and interspecific divergence was calculated in each re-
gion (Additional file 3), this being where most of the substi-
tutions found became accumulated, whilst neutrality could
not be ruled out for region B (p = 0.1). Functional/structural
constraint due to the presence of an s48/45 domain was
also probable for pv38, given this region’s low diversity,
two negatively selected sites and a statistically signifi-
cant KS > KN.
Linkage disequilibrium (LD) and recombination
Several statistics were calculated for determining possible
associations between polymorphisms and/or the presence
of recombination in pv38. ZnS did not reveal statistically
significant values, indicating that pv38 polymorphisms
were not associated. Lineal regression between linkage
disequilibrium (LD) and nucleotide distance revealed a re-
duction in LD as nucleotide distance increased, indicating
that intragenic recombination might have led to new vari-
ations being produced.
The ZZ statistic was calculated to confirm whether
recombination affected pv38 evolution, showing no sig-
nificant values (Table 2); however, 2 RM (minimum
recombination events) were found. The GARD method
(in Datamonkey web server) gave a recombination break-
point in position 524. Prior studies have suggested that
new haplotypes could be produced through recombin-
ation in spite of functional constraints [73]. Intragenic re-
combination could thus be one of the factors promoting
diversity in the pv38 gene. Crosslinking during recombin-
ation could produce new combinations between the gene’s
5′ (region A) and 3′ region (region B) as the breakpoint
found in this gene was located upstream of the region en-
coding the s48/45 domain (region B). As only one poly-
morphic site was found in pv12, the aforementioned tests
were not carried for this gene.
pv12 and pv38 should be considered for an antimalarial
vaccine
The lack of a totally effective vaccine against human malar-
ial parasites is at least partly due to high genetic diversity
found in proteins involved in red blood cell invasion. These
molecules’ constant exposure to the host’s immune system
allows the fixation of mutations generating an adaptive
advantage preventing their recognition. Antigens such as
pvmsp-1, pvdbp, pvmsp-3α, pvmsp-5, pvmsp-7C, pvmsp-
7H, pvmsp-7I and pvama-1 have shown high genetic diver-
sity which appears to be maintained by positive-balancing
selection [10-15,75-78]; however, other antigens are highly
conserved despite being exposed to the host’s immune sys-
tem. Surface antigens such as pvmsp-4, pvmsp-7A, pvmsp-7 K, pvmsp-8, pvmsp-10, pv230 or others in the rhoptries
(pvrap-1 and pvrap-2) appear to evolve more slowly due to
a possible functional constraint in their encoded proteins
[70,71,79-82]. Thus, most mutations have become elimi-
nated from the population, maintaining a conserved
protein structure, even throughout these parasites’ evo-
lutionary history [70,71]. The latter behaviour seems to
have been directing pv12 and pv38 evolution, highlighting
high conservation at both intra- and inter-species level
due to the influence of negative selection exerted on s48/
45 domains which are important for red blood cell recog-
nition [30]. Although antigens having low genetic diversity
are usually not immunogenic [83] nor do they induce
protection-inducing responses [84], some limited poly-
morphism antigens have been shown to be able to induce
immunogenicity and protection [85]. Therefore, pv12 and
pv38 (or their s48/45 domains) should be evaluated re-
garding vaccine development because immune responses
against 6-Cys family antigens appear to be directed against
structural epitopes in s48/45 domains [86-88], blocking
such domains should prevent invasion [30,88] and being
highly conserved and having a functional constraint,
allele-specific immune responses are thus avoided.
Conclusions
The p12 and p38 genes in P. vivax were seen to have low
genetic diversity; the regions encoding the s48/45 domains
seemed to be functionally or structurally constrained. Sev-
eral members of the 6-Cys family are found on the surface
of malaria parasites in every stage [28,36-39,69] and some
of them (e g, P48/45, P230) are considered to be promis-
ing (transmission-blocking) vaccine candidates [36,37,87].
Epitopes identified by monoclonal antibodies against this
type of protein are structural and have been localized
within s48/45 domains [86,87] which seem to be involved
in host-pathogen interaction [30,72]. Since pv12 and pv38
share structural characteristics with members of the 6-Cys
family, added to their antigenic characteristics [38-40] and
the low genetic diversity found in this study, the proteins
encoded by these genes or their functionally/structurally
constrained (conserved) regions could be born in mind
when designing a multistage, multi-antigen subunit-based
anti-malarial vaccine.
Additional files
Additional file 1: pv12 and pv38 haplotypes distribution in the
Colombian population. Haplotype distribution found in pv12 (A) and
pv38 (B) from 2007 to 2010.
Additional file 2: Synonymous substitution per synonymous site
rate (dS) and non-synonymous substitution per non-synonymous
site rate (dN) in s48/45 domains from pv12 and pv38 genes. No
statistically significant differences were found by codon-based Z-test or
Fisher’s exact tests. se: Standard error. pv12 s48/45 domain in region A:
nucleotides 82-471; pv12 s48/45 domain in region B: nucleotides 589-906;
Forero-Rodríguez et al. Malaria Journal 2014, 13:58 Page 10 of 12
http://www.malariajournal.com/content/13/1/58pv38 s48/45 domain in region B: nucleotides 481-852 -: There is no s48/
45 domain in the pv38 region. Numbering is based on the Sal-I reference
sequence.
Additional file 3: McDonald-Kreitman test for evaluating the action
of natural selection in pv12 and pv38 gene regions A and B. The
McDonald-Kreitman test was done using sequences obtained from
databases (worldwide isolates) together with Colombian ones, and just
with those obtained in the Colombian population. The interspecies
divergence data was obtained from comparing Plasmodium vivax
sequences with two related species: Plasmodium cynomolgi and
Plasmodium knowlesi. Significant values are underlined. pv12: region A,
nucleotides 1-546 and region B, nucleotides 547-1,095. pv38: region A,
nucleotides 1-459 and region B, nucleotides 460-1,065.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
JF-R devised the study, participated in designing it, performed the
experiments, made the population genetics analysis and wrote the
manuscript. DG-O devised and designed the study, helped perform the
experiments, carried out the population genetics analysis and wrote the
manuscript. MAP devised and coordinated the study, and helped to write
the manuscript. All the authors have read and approved the final manuscript.
Acknowledgements
We would especially like to thank Dr Sylvain Mousset who provided the
ALLELIX software for our analysis. We would also like to thank Jason Garry
for translating the manuscript and Professor Manuel E. Patarroyo for his
comments and suggestions. This work was financed by the “Departamento
Administrativo de Ciencia, Tecnología e Innovación (COLCIENCIAS)” through
contract RC # 0309-2013. JF-R received financing through COLCIENCIAS
cooperation agreement # 0757-2012.
Author details
1Molecular Biology and Immunology Department, Fundación Instituto de
Inmunología de Colombia (FIDIC), Carrera 50 No. 26-20, Bogotá, DC,
Colombia. 2Microbiology postgraduate programme, Universidad Nacional de
Colombia, Bogotá, DC, Colombia. 3School of Medicine and Health Sciences,
Universidad del Rosario, Bogotá, DC, Colombia.
Received: 14 September 2013 Accepted: 13 February 2014
Published: 18 February 2014
References
1. Rich SM, Ayala FJ: Progress in malaria research: the case for
phylogenetics. Adv Parasitol 2003, 54:255–280.
2. White NJ: Plasmodium knowlesi: the fifth human malaria parasite.
Clin Infect Dis 2008, 46:172–173.
3. WHO: World Malaria Report 2012. Geneva: World Health Organization; 2012.
http://www.who.int/malaria/publications/world_malaria_report_2012/
wmr2012_no_profiles.pdf.
4. Price RN, Tjitra E, Guerra CA, Yeung S, White NJ, Anstey NM: Vivax malaria:
neglected and not benign. Am J Trop Med Hyg 2007, 77:79–87.
5. Gething PW, Elyazar IR, Moyes CL, Smith DL, Battle KE, Guerra CA, Patil AP,
Tatem AJ, Howes RE, Myers MF, George DB, Horby P, Wertheim HF, Price
RN, Müeller I, Baird JK, Hay SI: A long neglected world malaria map:
Plasmodium vivax endemicity in 2010. PLoS Negl Trop Dis 2012, 6:e1814.
6. Drug resistance in malaria. http://www.who.int/csr/resources/publications/
drugresist/malaria.pdf.
7. Ranson H, Rossiter L, Ortelli F, Jensen B, Wang X, Roth CW, Collins FH,
Hemingway J: Identification of a novel class of insect glutathione
S-transferases involved in resistance to DDT in the malaria vector
Anopheles gambiae. Biochem J 2001, 359:295–304.
8. Carvalho LJ, Daniel-Ribeiro CT, Goto H: Malaria vaccine: candidate
antigens, mechanisms, constraints and prospects. Scand J Immunol 2002,
56:327–343.
9. Jones TR, Hoffman SL: Malaria vaccine development. Clin Microbiol Rev
1994, 7:303–310.10. Gomez A, Suarez CF, Martinez P, Saravia C, Patarroyo MA: High
polymorphism in Plasmodium vivax merozoite surface protein-5 (MSP5).
Parasitology 2006, 133:661–672.
11. Martinez P, Suarez CF, Cardenas PP, Patarroyo MA: Plasmodium vivax Duffy
binding protein: a modular evolutionary proposal. Parasitology 2004,
128:353–366.
12. Putaporntip C, Jongwutiwes S, Seethamchai S, Kanbara H, Tanabe K: Intragenic
recombination in the 3′ portion of the merozoite surface protein 1 gene of
Plasmodium vivax. Mol Biochem Parasitol 2000, 109:111–119.
13. Putaporntip C, Udomsangpetch R, Pattanawong U, Cui L, Jongwutiwes S:
Genetic diversity of the Plasmodium vivax merozoite surface protein-5
locus from diverse geographic origins. Gene 2010, 456:24–35.
14. Garzon-Ospina D, Lopez C, Forero-Rodriguez J, Patarroyo MA: Genetic diversity
and selection in three Plasmodium vivax merozoite surface protein 7
(Pvmsp-7) genes in a Colombian population. PLoS One 2012, 7:e45962.
15. Figtree M, Pasay CJ, Slade R, Cheng Q, Cloonan N, Walker J, Saul A:
Plasmodium vivax synonymous substitution frequencies, evolution and
population structure deduced from diversity in AMA 1 and MSP 1 genes.
Mol Biochem Parasitol 2000, 108:53–66.
16. Mascorro CN, Zhao K, Khuntirat B, Sattabongkot J, Yan G, Escalante AA, Cui
L: Molecular evolution and intragenic recombination of the merozoite
surface protein MSP-3alpha from the malaria parasite Plasmodium vivax
in Thailand. Parasitology 2005, 131:25–35.
17. Escalante AA, Lal AA, Ayala FJ: Genetic polymorphism and natural selection
in the malaria parasite Plasmodium falciparum. Genetics 1998, 149:189–202.
18. Chenet SM, Tapia LL, Escalante AA, Durand S, Lucas C, Bacon DJ: Genetic
diversity and population structure of genes encoding vaccine candidate
antigens of Plasmodium vivax. Malar J 2012, 11:68.
19. Takala SL, Plowe CV: Genetic diversity and malaria vaccine design, testing
and efficacy: preventing and overcoming ‘vaccine resistant malaria’.
Parasite Immunol 2009, 31:560–573.
20. Genton B, Reed ZH: Asexual blood-stage malaria vaccine development:
facing the challenges. Curr Opin Infect Dis 2007, 20:467–475.
21. Fluck C, Smith T, Beck HP, Irion A, Betuela I, Alpers MP, Anders R, Saul A,
Genton B, Felger I: Strain-specific humoral response to a polymorphic
malaria vaccine. Infect Immun 2004, 72:6300–6305.
22. Ouattara A, Takala-Harrison S, Thera MA, Coulibaly D, Niangaly A, Saye R,
Tolo Y, Dutta S, Heppner DG, Soisson L, Diggs CL, Vekemans J, Cohen J,
Blackwelder WC, Dube T, Laurens MB, Doumbo OK, Plowe CV: Molecular
basis of allele-specific efficacy of a blood-stage malaria vaccine: vaccine
development implications. J Infect Dis 2013, 207:511–519.
23. Zambrano-Villa S, Rosales-Borjas D, Carrero JC, Ortiz-Ortiz L: How protozoan
parasites evade the immune response. Trends Parasitol 2002, 18:272–278.
24. Richie TL, Saul A: Progress and challenges for malaria vaccines. Nature
2002, 415:694–701.
25. Kimura M: The neutral theory of molecular evolution. Cambridge
Cambridgeshire. New York: Cambridge University Press; 1983.
26. O’Donnell RA, De Koning-Ward TF, Burt RA, Bockarie M, Reeder JC, Cowman
AF, Crabb BS: Antibodies against merozoite surface protein (MSP)-1(19)
are a major component of the invasion-inhibitory response in individuals
immune to malaria. J Exp Med 2001, 193:1403–1412.
27. Nagao E, Seydel KB, Dvorak JA: Detergent-resistant erythrocyte membrane
rafts are modified by a Plasmodium falciparum infection. Exp Parasitol
2002, 102:57–59.
28. Sanders PR, Gilson PR, Cantin GT, Greenbaum DC, Nebl T, Carucci DJ,
McConville MJ, Schofield L, Hodder AN, Yates JR 3rd, Crabb BS: Distinct
protein classes including novel merozoite surface antigens in Raft-like
membranes of Plasmodium falciparum. J Biol Chem 2005, 280:40169–40176.
29. Arevalo-Pinzon G, Curtidor H, Vanegas M, Vizcaino C, Patarroyo MA,
Patarroyo ME: Conserved high activity binding peptides from the
Plasmodium falciparum Pf34 rhoptry protein inhibit merozoites in vitro
invasion of red blood cells. Peptides 2010, 31:1987–1994.
30. Garcia J, Curtidor H, Pinzon CG, Vanegas M, Moreno A, Patarroyo ME:
Identification of conserved erythrocyte binding regions in members of
the Plasmodium falciparum Cys6 lipid raft-associated protein family.
Vaccine 2009, 27:3953–3962.
31. Garcia Y, Puentes A, Curtidor H, Cifuentes G, Reyes C, Barreto J, Moreno A,
Patarroyo ME: Identifying merozoite surface protein 4 and merozoite
surface protein 7 Plasmodium falciparum protein family members
specifically binding to human erythrocytes suggests a new malarial
parasite-redundant survival mechanism. J Med Chem 2007, 50:5665–5675.
Forero-Rodríguez et al. Malaria Journal 2014, 13:58 Page 11 of 12
http://www.malariajournal.com/content/13/1/5832. Urquiza M, Rodriguez LE, Suarez JE, Guzman F, Ocampo M, Curtidor H,
Segura C, Trujillo E, Patarroyo ME: Identification of Plasmodium falciparum
MSP-1 peptides able to bind to human red blood cells. Parasite Immunol
1996, 18:515–526.
33. Rodriguez LE, Curtidor H, Urquiza M, Cifuentes G, Reyes C, Patarroyo ME:
Intimate molecular interactions of P. falciparum merozoite proteins
involved in invasion of red blood cells and their implications for vaccine
design. Chem Rev 2008, 108:3656–3705.
34. Barrero CA, Delgado G, Sierra AY, Silva Y, Parra-Lopez C, Patarroyo MA:
Gamma interferon levels and antibody production induced by two
PvMSP-1 recombinant polypeptides are associated with protective
immunity against P. vivax in Aotus monkeys. Vaccine 2005, 23:4048–4053.
35. Richards JS, Beeson JG: The future for blood-stage vaccines against
malaria. Immunol Cell Biol 2009, 87:377–390.
36. Van Dijk MR, Van Schaijk BC, Khan SM, Van Dooren MW, Ramesar J,
Kaczanowski S, Van Gemert GJ, Kroeze H, Stunnenberg HG, Eling WM, et al:
Three members of the 6-cys protein family of Plasmodium play a role in
gamete fertility. PLoS Pathog 2010, 6:e1000853.
37. Williamson KC: Pfs230: from malaria transmission-blocking vaccine
candidate toward function. Parasite Immunol 2003, 25:351–359.
38. Mongui A, Angel DI, Guzman C, Vanegas M, Patarroyo MA: Characterisation
of the Plasmodium vivax Pv38 antigen. Biochem Biophys Res Commun
2008, 376:326–330.
39. Moreno-Perez DA, Areiza-Rojas R, Florez-Buitrago X, Silva Y, Patarroyo ME,
Patarroyo MA: The GPI-anchored 6-Cys protein Pv12 is present in
detergent-resistant microdomains of Plasmodium vivax blood stage
schizonts. Protist 2013, 164:37–48.
40. Chen JH, Jung JW, Wang Y, Ha KS, Lu F, Lim CS, Takeo S, Tsuboi T, Han ET:
Immunoproteomics profiling of blood stage Plasmodium vivax infection
by high-throughput screening assays. J Proteome Res 2010, 9:6479–6489.
41. Prajapati SK, Joshi H, Shalini S, Patarroyo MA, Suwanarusk R, Kumar A,
Sharma SK, Eapen A, Dev V, Bhatt RM, Valecha N, Nosten F, Rizvi MA, Dash
AP: Plasmodium vivax lineages: geographical distribution, tandem repeat
polymorphism, and phylogenetic relationship. Malar J 2011, 10:374.
42. Imwong M, Pukrittayakamee S, Gruner AC, Renia L, Letourneur F,
Looareesuwan S, White NJ, Snounou G: Practical PCR genotyping protocols
for Plasmodium vivax using Pvcs and Pvmsp1. Malar J 2005, 4:20.
43. Neafsey DE, Galinsky K, Jiang RH, Young L, Sykes SM, Saif S, Gujja S,
Goldberg JM, Young S, Zeng Q, Chapman SB, Dash AP, Anvikar AR, Sutton
PL, Birren BW, Escalante AA, Barnwell JW, Carlton JM: The malaria parasite
Plasmodium vivax exhibits greater genetic diversity than Plasmodium
falciparum. Nat Genet 2012, 44:1046–1050.
44. Carlton JM, Adams JH, Silva JC, Bidwell SL, Lorenzi H, Caler E, Crabtree J,
Angiuoli SV, Merino EF, Amedeo P, Cheng Q, Coulson RM, Crabb BS, Del
Portillo HA, Essien K, Feldblyum TV, Fernandez-Becerra C, Gilson PR, Gueye
AH, Guo X, Kang’a S, Kooij TW, Korsinczky M, Meyer EV, Nene V, Paulsen I,
White O, Ralph SA, Ren Q, Sargeant TJ, et al: Comparative genomics of the
neglected human malaria parasite Plasmodium vivax. Nature 2008,
455:757–763.
45. Edgar RC: MUSCLE: multiple sequence alignment with high accuracy and
high throughput. Nucleic Acids Res 2004, 32:1792–1797.
46. Suyama M, Torrents D, Bork P: PAL2NAL: robust conversion of protein
sequence alignments into the corresponding codon alignments.
Nucleic Acids Res 2006, 34:W609–W612.
47. Librado P, Rozas J: DnaSP v5: a software for comprehensive analysis of
DNA polymorphism data. Bioinformatics 2009, 25:1451–1452.
48. Depaulis F, Veuille M: Neutrality tests based on the distribution of
haplotypes under an infinite-site model. Mol Biol Evol 1998,
15:1788–1790.
49. Tajima F: Statistical method for testing the neutral mutation hypothesis
by DNA polymorphism. Genetics 1989, 123:585–595.
50. Fu YX, Li WH: Statistical tests of neutrality of mutations. Genetics 1993,
133:693–709.
51. Fay JC, Wu CI: Hitchhiking under positive Darwinian selection. Genetics
2000, 155:1405–1413.
52. Fu YX: Statistical tests of neutrality of mutations against population
growth, hitchhiking and background selection. Genetics 1997,
147:915–925.
53. Zhang J, Rosenberg HF, Nei M: Positive Darwinian selection after gene
duplication in primate ribonuclease genes. Proc Natl Acad Sci U S A 1998,
95:3708–3713.54. Tamura K, Peterson D, Peterson N, Stecher G, Nei M, Kumar S: MEGA5:
molecular evolutionary genetics analysis using maximum likelihood,
evolutionary distance, and maximum parsimony methods. Mol Biol Evol
2011, 28:2731–2739.
55. Kosakovsky Pond SL, Frost SD: Not so different after all: a comparison of
methods for detecting amino acid sites under selection. Mol Biol Evol
2005, 22:1208–1222.
56. Pond SL, Frost SD, Grossman Z, Gravenor MB, Richman DD, Brown AJ:
Adaptation to different human populations by HIV-1 revealed by
codon-based analyses. PLoS Comput Biol 2006, 2:e62.
57. Murrell B, Wertheim JO, Moola S, Weighill T, Scheffler K, Kosakovsky Pond
SL: Detecting individual sites subject to episodic diversifying selection.
PLoS Genet 2012, 8:e1002764.
58. Murrell B, Moola S, Mabona A, Weighill T, Sheward D, Kosakovsky Pond SL,
Scheffler K: FUBAR: a fast, unconstrained bayesian approximation for
inferring selection. Mol Biol Evol 2013, 30:1196–1205.
59. Jukes TH, Cantor CR: Evolution of protein molecules. In Mammalian Protein
Metabolism. Edited by Munro HN. New York: Academic Press; 1969.
60. McDonald JH, Kreitman M: Adaptive protein evolution at the Adh locus in
Drosophila. Nature 1991, 351:652–654.
61. Egea R, Casillas S, Barbadilla A: Standard and generalized McDonald-
Kreitman test: a website to detect selection by comparing different
classes of DNA sites. Nucleic Acids Res 2008, 36:W157–W162.
62. Kelly JK: A test of neutrality based on interlocus associations. Genetics
1997, 146:1197–1206.
63. Rozas J, Gullaud M, Blandin G, Aguade M: DNA variation at the rp49 gene
region of Drosophila simulans: evolutionary inferences from an unusual
haplotype structure. Genetics 2001, 158:1147–1155.
64. Hudson RR, Kaplan NL: Statistical properties of the number of
recombination events in the history of a sample of DNA sequences.
Genetics 1985, 111:147–164.
65. Kosakovsky Pond SL, Posada D, Gravenor MB, Woelk CH, Frost SD:
Automated phylogenetic detection of recombination using a genetic
algorithm. Mol Biol Evol 2006, 23:1891–1901.
66. Delport W, Poon AF, Frost SD, Kosakovsky Pond SL: Datamonkey 2010: a
suite of phylogenetic analysis tools for evolutionary biology.
Bioinformatics 2010, 26:2455–2457.
67. Taylor JE, Pacheco MA, Bacon DJ, Beg MA, Machado RL, Fairhurst RM,
Herrera S, Kim JY, Menard D, Póvoa MM, Villegas L, Mulyanto, Snounou G,
Cui L, Zeyrek FY, Escalante AA: The evolutionary history of Plasmodium
vivax as inferred from mitochondrial genomes: parasite genetic diversity
in the Americas. Mol Biol Evol 2013, 30:2050–2064.
68. Tetteh KK, Stewart LB, Ochola LI, Amambua-Ngwa A, Thomas AW, Marsh K,
Weedall GD, Conway DJ: Prospective identification of malaria parasite
genes under balancing selection. PLoS One 2009, 4:e5568.
69. Tonkin ML, Arredondo SA, Loveless BC, Serpa JJ, Makepeace KA, Sundar N,
Petrotchenko EV, Miller LH, Grigg ME, Boulanger MJ: Structural and
biochemical characterization of Plasmodium falciparum 12 (Pf12) reveals
a unique interdomain organization and the potential for an antiparallel
arrangement with Pf41. J Biol Chem 2013, 288:12805–12817.
70. Pacheco MA, Ryan EM, Poe AC, Basco L, Udhayakumar V, Collins WE,
Escalante AA: Evidence for negative selection on the gene encoding
rhoptry-associated protein 1 (RAP-1) in Plasmodium spp. Infect Genet Evol
2010, 10:655–661.
71. Pacheco MA, Elango AP, Rahman AA, Fisher D, Collins WE, Barnwell JW,
Escalante AA: Evidence of purifying selection on merozoite surface
protein 8 (MSP8) and 10 (MSP10) in Plasmodium spp. Infect Genet Evol
2012, 12:978–986.
72. Arredondo SA, Cai M, Takayama Y, MacDonald NJ, Anderson DE, Aravind L,
Clore GM, Miller LH: Structure of the Plasmodium 6-cysteine s48/45
domain. Proc Natl Acad Sci U S A 2012, 109:6692–6697.
73. Reeder JC, Wapling J, Mueller I, Siba PM, Barry AE: Population genetic
analysis of the Plasmodium falciparum 6-cys protein Pf38 in Papua New
Guinea reveals domain-specific balancing selection. Malar J 2011, 10:126.
74. Parsch J, Zhang Z, Baines JF: The influence of demography and weak
selection on the McDonald-Kreitman test: an empirical study in Drosophila.
Mol Biol Evol 2009, 26:691–698.
75. Ord R, Polley S, Tami A, Sutherland CJ: High sequence diversity and
evidence of balancing selection in the Pvmsp3alpha gene of
Plasmodium vivax in the Venezuelan Amazon. Mol Biochem Parasitol
2005, 144:86–93.
Forero-Rodríguez et al. Malaria Journal 2014, 13:58 Page 12 of 12
http://www.malariajournal.com/content/13/1/5876. Kang JM, Ju HL, Kang YM, Lee DH, Moon SU, Sohn WM, Park JW, Kim TS,
Na BK: Genetic polymorphism and natural selection in the C-terminal 42
kDa region of merozoite surface protein-1 among Plasmodium vivax
Korean isolates. Malar J 2012, 11:206.
77. Zakeri S, Sadeghi H, Mehrizi AA, Djadid ND: Population genetic structure
and polymorphism analysis of gene encoding apical membrane antigen-1
(AMA-1) of Iranian Plasmodium vivax wild isolates. Acta Trop 2013,
126:269–279.
78. Ju HL, Kang JM, Moon SU, Kim JY, Lee HW, Lin K, Sohn WM, Lee JS, Kim TS,
Na BK: Genetic polymorphism and natural selection of Duffy binding
protein of Plasmodium vivax Myanmar isolates. Malar J 2012, 11:60.
79. Garzon-Ospina D, Romero-Murillo L, Tobon LF, Patarroyo MA: Low genetic
polymorphism of merozoite surface proteins 7 and 10 in Colombian
Plasmodium vivax isolates. Infect Genet Evol 2011, 11:528–531.
80. Garzon-Ospina D, Romero-Murillo L, Patarroyo MA: Limited genetic
polymorphism of the Plasmodium vivax low molecular weight rhoptry
protein complex in the Colombian population. Infect Genet Evol 2010,
10:261–267.
81. Martinez P, Suarez CF, Gomez A, Cardenas PP, Guerrero JE, Patarroyo MA:
High level of conservation in Plasmodium vivax merozoite surface
protein 4 (PvMSP4). Infect Genet Evol 2005, 5:354–361.
82. Doi M, Tanabe K, Tachibana S, Hamai M, Tachibana M, Mita T, Yagi M,
Zeyrek FY, Ferreira MU, Ohmae H, Kaneko A, Randrianarivelojosia M,
Sattabongkot J, Cao YM, Horii T, Torii M, Tsuboi T: Worldwide sequence
conservation of transmission-blocking vaccine candidate Pvs230 in
Plasmodium vivax. Vaccine 2011, 29:4308–4315.
83. Patarroyo MA, Calderon D, Moreno-Perez DA: Vaccines against Plasmodium
vivax: a research challenge. Expert Rev Vaccines 2012, 11:1249–1260.
84. Giraldo MA, Arevalo-Pinzon G, Rojas-Caraballo J, Mongui A, Rodriguez R,
Patarroyo MA: Vaccination with recombinant Plasmodium vivax MSP-10
formulated in different adjuvants induces strong immunogenicity but no
protection. Vaccine 2009, 28:7–13.
85. Rojas-Caraballo J, Mongui A, Giraldo MA, Delgado G, Granados D, Millan-
Cortes D, Martinez P, Rodriguez R, Patarroyo MA: Immunogenicity and
protection-inducing ability of recombinant Plasmodium vivax rhoptry-
associated protein 2 in Aotus monkeys: a potential vaccine candidate.
Vaccine 2009, 27:2870–2876.
86. Carter R, Coulson A, Bhatti S, Taylor BJ, Elliott JF: Predicted disulfide-bonded
structures for three uniquely related proteins of Plasmodium falciparum,
Pfs230, Pfs48/45 and Pf12. Mol Biochem Parasitol 1995, 71:203–210.
87. Tachibana M, Sato C, Otsuki H, Sattabongkot J, Kaneko O, Torii M, Tsuboi T:
Plasmodium vivax gametocyte protein Pvs230 is a transmission-blocking
vaccine candidate. Vaccine 2012, 30:1807–1812.
88. Feller T, Thom P, Koch N, Spiegel H, Addai-Mensah O, Fischer R, Reimann A,
Pradel G, Fendel R, Schillberg S, Scheuermayer M, Schinkel H: Plant-based
production of recombinant Plasmodium surface protein pf38 and evaluation
of its potential as a vaccine candidate. PLoS One 2013, 8:e79920.
doi:10.1186/1475-2875-13-58
Cite this article as: Forero-Rodríguez et al.: Low genetic diversity and
functional constraint in loci encoding Plasmodium vivax P12 and P38
proteins in the Colombian population. Malaria Journal 2014 13:58.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
